Novel biomarkers for risk of prostate cancer: Results from a case-control study

Prostate

Volumn 69, Issue 1, 2009, Pages 41-48

  Yang, Li ^a   Gaikwad, Nilesh W ^a   Meza, Jane ^b   Cavalieri, Ercole L ^a   Muti, Paola ^c   Trock, Bruce ^d   Rogan, Eleanor G ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Depurinating estrogen DNA adducts; Prostate cancer

Indexed keywords

ANDROGEN; BIOLOGICAL MARKER; DNA; ESTROGEN; TUMOR MARKER;

ADULT; AGED; ANDROGEN URINE LEVEL; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DNA ADDUCT; EARLY DIAGNOSIS; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; ESTROGEN URINE LEVEL; HORMONE URINE LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SOLID PHASE EXTRACTION; STEROID URINE LEVEL; TANDEM MASS SPECTROMETRY; URINALYSIS; BIOSYNTHESIS; MIDDLE AGED; PROSTATE TUMOR; RISK; RISK FACTOR; URINE;

AGED; AGED, 80 AND OVER; ANDROGENS; CASE-CONTROL STUDIES; DNA ADDUCTS; EARLY DIAGNOSIS; ESTROGENS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 58149328544     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20850     Document Type: Article

References (34)

1. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986;76:45-48.
2. Cerhan JR, Parker AS, Putnam SD, Chiu BC, Lynch CF, Cohen MB, Torner JC, Cantor KP. Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol Biomarkers Prev 1999;8:53-60.
3. Wu K, Erdman JW Jr, , Schwartz SJ, Platz EA, Leitzmann M, Clinton SK, DeGroff V, Willett WC, Giovannucci E. Plasma and dietary carotenoids, and the risk of prostate cancer: A nested case-control study. Cancer Epidemiol Biomarkers Prev 2004;13:260-269.
4. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: Potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005;14:2257-2260.
5. Bosland MC. Sex steroids and prostate carcinogenesis: Integrated, multifactorial working hypothesis. Ann NY Acad Sci 2006;1089:168-176.
6. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006;11:1388-1413.
7. Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977;37:1929-1933.
8. Carter HB, Pearson JD, Metter EJ, Chan DW, Andres R, Fozard JL, Rosner W, Walsh PC. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995;27:25-31.
9. Hsing AW. Hormones and prostate cancer: Where do we go from here? J Natl Cancer Inst 1996;88:1093-1095.
10. Hsing AW. Hormones and prostate cancer: What's next? Epidemiol Rev 2001;23:42-58.
11. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: Current perspectives and future directions. Prostate 2002;52:213-235.
12. Travis RC, Key TJ, Allen NE, Appleby PN, Roddam AW, Rinaldi S, Egevad L, Gann PH, Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF, Tjonneland A, Overvad K, Kiemeney L, Bueno-de-Mesquita HB, Bingham S, Khaw KT,Tumino R, Sieri S, Vineis P, Palli D, Quiros JR, Ardanaz E, Chirlaque MD, Larranaga N, Gonzalez C, Sanchez MJ, Trichopoulou A, Bikou C, Trichopoulos D, Stattin P, Jenab M, Ferrari P, Slimani N, Riboli E, Kaaks R. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007;121:1331-1338.
13. Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2000;27:39-66.
14. Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP. Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 2004;89:2434-2441.
15. Carruba G. Estrogens and mechanisms of prostate cancer progression. Ann NY Acad Sci 2006;1089:201-217.
16. Prins GS, Huang L, Birch L, Pu Y. The role of estrogens in normal and abnormal development of the prostate gland. Ann NY Acad Sci 2006;1089:1-13.
17. Carruba G. Estrogen and prostate cancer: An eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007;102:899-911.
18. Leav I, Merk FB, Kwan PW, Ho SM. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 1989;15:23-40.
19. Prins GS. Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. Endocrinology 1992;130:3703-3714.
20. Prins GS, Woodham C, Lepinske M, Birch L. Effects of neonatal estrogen exposure on prostatic secretory genes and their correlation with androgen receptor expression in the separate prostate lobes of the adult rat. Endocrinology 1993;132:2387-2398.
21. Santti R, Newbold RR, Makela S, Pylkkanen L, McLachlan JA. Developmental estrogenization and prostatic neoplasia. Prostate 1994;24:67-78.
22. Putz O, Prins GS. Prostate gland development and estrogenic imprinting. In: Burnstein KL, editor. Steroid hormones and cell cycle regulation. Boston, MA: Kluwer; 2002. pp. 73-89.
23. Woodham C, Birch L, Prins GS. Neonatal estrogen down-regulates prostatic androgen receptor through a proteosome-mediated protein degradation pathway. Endocrinology 2003;144:4841-4850.
24. Hill P, Garbaczewski L, Walker AR. Age, environmental factors and prostatic cancer. Med Hypotheses 1984;14:29-39.
25. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339:887-889.
26. Markushin Y, Gaikwad N, Zhang H, Kapke P, Rogan EG, Cavalieri EL, Trock BJ, Pavlovich C, Jankowiak R. Potential biomarker for early risk assessment of prostate cancer. Prostate 2006;66:1565-1571.
27. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616.
28. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, Sutter T. Catechol estrogen quinones as initiators of breast and other human cancers: Implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta Rev Cancer 2006;1766:63-78.
29. Gaikwad NW, Yang L, Muti P, Meza JL, Pruthi S, Ingle JN, Rogan EG, Cavalieri EL. The molecular etiology of breast cancer: Evidence from biomarkers of risk. Int J Cancer 2008;122:1949-1957.
30. Ragavan N, Hewitt R, Cooper LJ, Ashton KM, Hindley AC, Nicholson CM, Fullwood NJ, Matanhelia SS, Martin FL. CYP1B1 expression in prostate is higher in the peripheral than in the transition zone. Cancer Lett 2004;215:69-78.
31. Sissung TM, Price DK, Sparreboom A, Figg WD. Pharmacogenetics and regulation of human cytochrome P450 1B1: Implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 2006;4:135-150.
32. Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:969-978.
33. Spink DC, Spink BC, Cao JQ, DePasquale JA, Pentecost BT, Fasco MJ, Li Y, Sutter TR. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 1998;19:291-298.
34. Gaikwad NW, Rogan EG, Cavalieri EL. Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones. Free Radic Biol Med 2007;43:1289-1298.